Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists
CA 2428519 A1 · Owner: Merck Patent Gesellschaft Mit Beschraenkter Haftung · Inventors: Bartoszyk, Gerd
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Use of compounds being combined selective dopamine D2 receptor antagonists and 5-HT1A receptor agonists, in particular (R)-(-)-2-5-4 fluorophenyl)-3pyridylmethyl-aminomethyl-chromane or a physiologically acceptable salt thereof or N-(4'-fluoro-3-biphenylmethyl)-N-2-(3-cycanophenoxy-ethyl)-amine or a physiologically acceptable salt thereof for the manufacture of a medicament , for use in veterinary medicine for the treatment of self directed traumatic disorders associated with behavioral stressors compulsive disorders , associated with behavioral stressors and/or anxiety disorders associated with behavioral stressors.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 25, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 25, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 25, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.